Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer

Molecular Biotechnology

Volumn 54, Issue 3, 2013, Pages 913-919

  Petriella, Daniela ^a   Galetta, Domenico ^a   Rubini, Vincenza ^a   Savino, Eufemia ^a   Paradiso, Angelo ^a   Simone, Giovanni ^a   Tommasi, Stefania ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

FNA; miRNA; NSCLC

Indexed keywords

EPIGENETIC ANALYSIS; FNA; GENETIC INFORMATION; HISTOLOGICAL TISSUE; MIRNA; NON SMALL CELL LUNG CANCER; NSCLC; TYROSINE KINASE INHIBITOR;

AMINO ACIDS; BIOLOGICAL ORGANS; CYTOLOGY; DIAGNOSIS; DISEASES; GENE EXPRESSION; HISTOLOGY; PATIENT TREATMENT; TISSUE;

RNA;

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MICRORNA; MICRORNA 155; MICRORNA 21; MICRORNA 7; MICRORNA LET7A; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; DNA DETERMINATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID BASED CYTOLOGY; LUNG NON SMALL CELL CANCER; PATHOGENESIS; RNA ANALYSIS;

BIOPSY, FINE-NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; HISTOCYTOCHEMISTRY; HUMANS; LUNG NEOPLASMS; MICRORNAS; RNA, MESSENGER;

EID: 84882927774     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-012-9640-6     Document Type: Article

References (31)

1. Travis, W. D.; Brambilla, E.; Muller-Hermelink, H. K.; et al. (2004). World Health Organization. Tumors of the lung, pleura thymus, and heart. Classification of tumors. Lyon: IARC Press.
2. Fojo, T.; et al. (2007). Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resistance Updates, 10, 59-67.
3. Costanzo, R.; Piccirillo, M. C.; Sandomenico, C.; et al. (2011). Gefitinib in non small cell lung cancer. Journal of Biomedicine and Biotechnology, 2011, 815269.
4. Lynch, T. J.; Bell, D. W.; Sordella, R.; et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129-2139.
5. Pao, W.; Miller, V. A.; Politi, K. A.; et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed, 2, e73.
6. Massarelli, E.; Varella-Garcia, M.; Tang, X.; et al. (2007). KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clinical Cancer Research, 13, 2890-2896.
7. Hummel, R.; Hussey, D. J.; Haier, J. (2010). MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumor type. European Journal of Cancer, 2, 298-311.
8. Markou, A.; Liang, Y.; Lianidou, E. (2011). Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine, 49, 1591-1603.
9. Saito, M.; Schetter, A. J.; Mollerup, S.; et al. (2011). The association of microRNA expression with prognosis and progression in early stage, non small cell lung adenocarcinoma: A retrospective analysis of three cohorts. Clinical Cancer Research, 17, 1875-1882.
10. Yanaihara, N.; Caplen, N.; Bowman, E.; et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-198.
11. Takamizawa, J.; et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Research, 64, 3753-3756.
12. Chou, Y. T.; Lin, H. H.; Lien, Y. C.; et al. (2010). EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Research, 70, 8822-8831.
13. Pilotti, S.; Rilke, F.; Gribaudi, G.; Damascelli, B. (2010). Fine needle aspiration biopsy cytology of primary and metastatic pulmonary tumors. Acta Cytologica, 26, 661-666.
14. Nikolaidis, G.; Raji, O.; Markopoulou, S.; et al. (2012). DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Research, 72, 5692-5701.
15. Leng, S.; Do, K.; Yingling, M. C.; et al. (2012). Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clinical Cancer Research, 18, 3387-3395.
16. Kulawik, J.; Gornicka, B.; Krenke, R.; et al. (2010). The value of cytological diagnosis of small cell lung cancer. Pneumonologia i Alergologia Polska, 78, 203-210.
17. Schreiber, G.; McCrory, D. C. (2003). Performance characteristics of different modalities for diagnosis of suspected lung cancer: Summary of published evidence. Chest, 123, 115S-128S.
18. Delgrado, P. I.; Jorda, M.; Ganjeie-Azar, P. (2000). Small cell lung carcinoma versus other lung malignancies: Diagnosis by fine-needle aspiration cytology. Cancer, 90, 279-285.
19. Dey, P.; Luthra, U. K.; George, J.; et al. (2000). Comparison of thinprep and conventional preparation on fine needle aspiration cytology material. Acta Cytologica, 44, 46-50.
20. Tisserand, P.; Fouquet, C.; Marck, V.; et al. (2003). ThinPrep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis: Application to p53 mutation analysis. Cancer, 99, 223-232.
21. Paradiso, A.; Tommasi, S.; Pinto, R.; Carpagnano, G. E.; Foschino-Barbaro, M. P. (2008). Exhaled breath condensate is not suitable to detect EGFR somatic mutations. European Respiratory Journal, 32, 1126-1127.
22. Tommasi, S.; Pinto, R.; Petriella, D.; et al. (2011). Oncosuppressor methylation: A possible key role in colon metastatic progression. Journal of Cellular Physiology, 226, 1934-1939.
23. Schmittgen, T. D.; Livak, K. J. (2008). Analyzing real-time PCR data by the comparative CT method. Nature Protocols, 6, 1101-1108.
24. Kontzoglou, K.; Moulakakis, K. G.; Alexiou, D.; et al. (2007). The role of liquid-based cytology in the investigation of colorectal lesions: A cytohistopathological correlation and evaluation of diagnostic accuracy. Langenbeck's Archives of Surgery, 392, 189-195.
25. Schuurbiers, O. C.; Looijen-Salamon, M. G.; Ligtenberg, M. J.; Van der Heijden, H. F. (2010). A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. Journal of Thoracic Oncology, 5, 1664-1667.
26. Van Eijk, R.; Licht, J.; Schrumpf, M.; et al. (2011). Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS ONE, 6, e17791.
27. Mapelle, U.; De Rosa, N.; Rocco, D.; et al. (2012). EGFR and KRAS mutations detection on lung cancer liquid-based cytology: A pilot study. Journal of Clinical Pathology, 65, 87-91.
28. Nikiforova, M. N.; Tseng, G. C.; Steward, D.; Diorio, D.; Nikiforov, Y. E. (2008). MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. Journal of Clinical Endocrinology and Metabolism, 93, 1600-1608.
29. Szafranska, A. E.; Doleshal, M.; Edmunds, H. S.; et al. (2008). Analysis of MicroRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clinical Chemistry, 54, 1716-1724.
30. Ellis, M.; Davis, N.; Coop, A.; et al. (2002). Development and validation of method for using breast core needle biopsies for gene expression microarray analyses. Clinical Cancer Research, 8, 1155-1166.
31. Sotiriou, C.; Powles, T.; Dowsett, M.; et al. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research, 4, R3.